Table 1.
List of companies with active RNAi mediator drug programs.
| Generic Name | Status | Originator | Indication |
|---|---|---|---|
| NUC‐B100 | Phase I | Nucleonics | Infection, hepatitis‐B virus |
| SPC‐3649 | Phase I | Santaris Pharma | Infection, hepatitis‐C virus |
| RNAi HIV therapy (Benitec 1) | Phase I | Benitec | Infection, HIV/AIDS |
| Tenascin‐C RNAi | Phase I | Senetek | Cancer, brain |
| CALAA‐01 | Phase I | Calando | Cancer, unspecified |
| TD‐101 | Phase I | TransDerm | Pachyonychia congenita |
| ALN‐VSP02 | Phase I | Alnylam | Liver cancer |
| ALN‐RSV01 | Phase II | Alnylam | Infection, respiratory syncytial virus |
| AKIi‐5 | Phase II | Quark | Renal failure |
| RTP‐801i‐14 | Phase II | Quark | Macular degeneration, age‐related, wet |
| AGN‐211745 | Phase II | Allergan | AMD and Choroidal neovascularization (CNV) infection |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.